Ja, dann wohl heute keine Zahlen zum Finanzergebnis Q2.
Wird vom 31.08.20 auf bis zum 15.10.2020 verschoben lt. News
Originaltext:
Vancouver, British Columbia / August 28, 2020 – WPD Pharmaceuticals Inc. (the
“Company”) (CSE: WBIO) (FSE: 8SV1), announces that the Company will be extending its
filing financial results for the second quarter ended June 30, 2020 beyond the initial due date of
August 31, 2020. WPD will file its interim statements for Q2 by the permitted extension date of
October 15. 2020, as permitted pursuant to BC Instrument 51-517 Temporary Exemption from
Certain Corporate Finance Requirements with Deadlines during the Period from June 2 to
August 31, 2020 (“BCI 51-517”).
The Company will be relying on the temporary exemption pursuant to BCI 51-517 in respect to
the following provisions:
• the requirement to file interim financial statements for the six months ended June 30,
2020 (the “Financial Statements”) within 60 days after the end of the Company's
interim period as required by section 4.4(b) of National Instrument 51-102 Continuous
Disclosure (“NI 51-102”);
• the requirement to file management discussion and analysis (the “MD&A”) for the period
covered by the Financial Statements within 60 days after the end of the Company's
interim period as required by section 5.1(2) of NI 51-102; and
• the requirement to file certifications of the Financial Statements (the “Certificates” and
together with the Financial Statements, the “Interim Filings”) pursuant to section 5.1 of
National Instrument 52-109 Certification of Disclosure in Issuer’s Annual and Interim
Filings and section 4.4(b) [being the filing deadline for interim financial statements] of NI
51-102.
The Company confirms that there have been no material developments, other than those
disclosed through news releases and Form 7 Monthly Progress Reports filed on the Company’s
profile with the Canadian Securities Exchange, since the filing of its condensed interim
consolidated financial statements for the three months ended March 31, 2020.
Additionally, the Company advises that management and other insiders of the Company are
subject to a trading black-out policy as described, in principle, in section 9 of National Policy 11-
207, Failure to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.
Zurück
Weiter
